Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 in Combination with Cabozantinib for Treatment of Patients with Advanced Renal Cell Carcinoma

by NASDAQ Market News April 18, 2018

NASDAQ Market News
Click here to email author

Actinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D., Ph.D. as Vice President, Clinical Development

Trillium Therapeutics Reports TTI-622 Preclinical Data at the 2018 AACR Annual Meeting

Ads